Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y 12 receptors in vitro

Platelets

Volumn 27, Issue 3, 2016, Pages 191-195

  Judge, Heather M ^a   Buckland, Robert J ^a   Jakubowski, Joseph A ^b   Storey, Robert F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Cangrelor; Clopidogrel; P2Y12; Platelet; Prasugrel

Indexed keywords

CANGRELOR; CLOPIDOGREL; DRUG METABOLITE; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; THIENOPYRIDINE DERIVATIVE; UNCLASSIFIED DRUG; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; PRIORITY JOURNAL; THROMBOCYTE; ANALOGS AND DERIVATIVES; BINDING COMPETITION; BLOOD CLOTTING PARAMETERS; METABOLISM;

ADENOSINE MONOPHOSPHATE; BINDING, COMPETITIVE; HUMANS; IN VITRO TECHNIQUES; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TICLOPIDINE;

EID: 84939207230     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2015.1069809     Document Type: Article

References (21)

1. Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61 (15): 1601-1606
2. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, et al. Randomised assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5 (6): 797-804
3. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368 (14): 1303-1313
4. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomised controlled trial. JAMA 2012; 307 (3): 265-274
5. Tang XF, Fan JY, Meng J, Jin C, Yuan JQ, Yang YJ. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomised trials. Atherosclerosis 2014; 233 (2): 568-578
6. Wallentin L. P2Y(12) inhibitors: Differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009; 30 (16): 1964-1977
7. Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008; 99 (1): 215-222
8. Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ. The disp osition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007; 35 (7): 1096-1104
9. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25 (4): 357-374
10. European Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/21504 [last accessed 12 June 2015]
11. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29 (1): 21-30
12. Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: A direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 2010; 50 (1): 27-35
13. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001; 85 (3): 401-407
14. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121 (4): 527-534
15. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 2008; 6 (7): 1153-1159
16. Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M, Niitsu Y, Asai F. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrels active metabolite. J Thromb Haemost 2007; 5 (7): 1545-1551
17. Schneider DJ, Seecheran N, Raza SS, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis 2015; 26 (1): 42-48
18. Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets 2008; 19 (2): 125-133
19. Angiolillo DJ, Schneider DJ, Bhatt DL, French WJ, Price MJ, Saucedo JF, Shaburishvili T, Huber K, Prats J, Liu T, et al. Pharmacodynamic effects of cangrelor and clopidogrel: The platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis 2012; 34 (1): 44-55
20. Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv 2014; 7 (4): 435-442
21. Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, et al. Randomised double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study. Circulation 2009; 120 (25): 2577-2585